SAB Biotherapeutics Inc
Research SAB Biotherapeutics Inc (SABS) on Bullrun: market cap USD 318.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSABS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 318.11M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 22.49M
- Free cash flow-USD 11.43M
Valuation Snapshot
latest market cap is USD 318.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | USD 13.27M | -USD 45.71M | n/a | -0.79 | USD 10.50M | USD 5.95M | USD 151.49M |
| FY2024 | USD 1.32M | -USD 34.11M | -USD 34.63M | n/a | -3.68 | USD 8.90M | USD 4.67M | USD 25.97M |
| FY2023 | USD 2.24M | -USD 42.19M | -USD 25.32M | n/a | -7.64 | USD 56.57M | USD 5.91M | USD 57.30M |
| FY2022 | USD 23.90M | -USD 18.74M | -USD 25.63M | n/a | -4.31 | USD 15.05M | USD 6.09M | USD 31.06M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 318.11M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 178.06M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 35.20M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 63.47M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 29.73M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 339.63M | n/a | n/a | n/a |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SAB Biotherapeutics Inc's market cap?
SAB Biotherapeutics Inc's market capitalization is USD 318.11M.
What does SAB Biotherapeutics Inc do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.